Why AbbVie Moved Risk Assessment to the Draft Protocol Stage

Ann Hale, Head of Study Risk Management and Central Monitoring at AbbVie, discusses the company's shift toward conducting risk assessments earlier in the protocol development process using cross-functional teams. She emphasizes the importance of data criticality assessments and asking the fundamental question "What is truly critical?" to identify genuine showstoppers versus nice-to-have data points.